For research use only. Not Intended for Therapeutic Use!
|IC50:||1 uM |
|We match the lowest price on market.|
FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 uM; 5–10 times lower than the IC50 of fatostatin (~10 μM).
IC50 value: 1 uM 
Target: SREBP inhibitor
FGH10019 is a methanesulfonamide derivative of fatostatin, exhibited the highest activity in a cell-based assay, and exhibited better in vitro and in vivo physicochemical properties than fatostatin or the other derivatives that were synthesized and evaluated. is the most appropriate molecule for further testing in animal models, and this testing is currently under way.
. Kamisuki S, et al. Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins. J Med Chem. 2011 Jul 14;54(13):4923-7.